Leerink Swann Reaffirms “Outperform” Rating for Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. (NASDAQ:KPTI)‘s stock had its “outperform” rating reaffirmed by stock analysts at Leerink Swann in a research note issued on Friday. They presently have a $18.00 price target on the stock. Leerink Swann’s price target points to a potential upside of 88.28% from the stock’s previous close.
A number of other research firms also recently weighed in on KPTI. Robert W. Baird reissued a “positive” rating and set a $16.00 target price on shares of Karyopharm Therapeutics in a research report on Tuesday, September 6th. Vetr downgraded shares of Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating and set a $11.00 target price for the company. in a research report on Wednesday, August 31st. S&P Equity Research decreased their target price on shares of Karyopharm Therapeutics from $9.06 to $7.55 in a research report on Tuesday, August 30th. Jefferies Group reissued a “buy” rating and set a $12.00 target price on shares of Karyopharm Therapeutics in a research report on Thursday, September 8th. Finally, HC Wainwright increased their target price on shares of Karyopharm Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Thursday, September 8th. Two equities research analysts have rated the stock with a sell rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. Karyopharm Therapeutics has an average rating of “Buy” and a consensus target price of $16.04.
Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded down 1.54% during mid-day trading on Friday, hitting $9.56. 166,190 shares of the stock were exchanged. The stock’s market capitalization is $344.05 million. The stock’s 50 day moving average price is $9.04 and its 200-day moving average price is $8.40. Karyopharm Therapeutics has a 12-month low of $4.83 and a 12-month high of $19.41.
Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, August 4th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by $0.08. On average, equities research analysts expect that Karyopharm Therapeutics will post ($3.22) EPS for the current fiscal year.
Institutional investors have recently modified their holdings of the company. Metropolitan Life Insurance Co. NY purchased a new position in shares of Karyopharm Therapeutics during the second quarter worth about $136,000. Nationwide Fund Advisors boosted its position in shares of Karyopharm Therapeutics by 38.3% in the second quarter. Nationwide Fund Advisors now owns 21,258 shares of the company’s stock worth $143,000 after buying an additional 5,886 shares in the last quarter. ProShare Advisors LLC boosted its position in shares of Karyopharm Therapeutics by 1.3% in the second quarter. ProShare Advisors LLC now owns 29,655 shares of the company’s stock worth $199,000 after buying an additional 376 shares in the last quarter. Highbridge Capital Management LLC purchased a new position in shares of Karyopharm Therapeutics during the second quarter worth about $200,000. Finally, Alliancebernstein L.P. boosted its position in shares of Karyopharm Therapeutics by 24.2% in the second quarter. Alliancebernstein L.P. now owns 34,930 shares of the company’s stock worth $234,000 after buying an additional 6,800 shares in the last quarter. Institutional investors own 55.71% of the company’s stock.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.
Receive News & Stock Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related stocks with our FREE daily email newsletter.